Bibliography
- Hay N . The Akt-mTOR tango and its relevance to cancer.Cancer Cell8, 179–183 (2005).
- Faivre S , KroemerG, RaymondE. Current development of mTOR inhibitors as anticancer agents.Nat. Rev. Drug Discov.5, 671–688 (2006).
- Baldo P , CeccoS, GiacominEet al. mTOR pathway and mTOR inhibitors as agents for cancer therapy. Curr. Cancer Drug Targets 8, 647–665 (2008).
- Fingar DC , BlenisJ. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression.Oncogene23, 3151–3171(2004).
- Guertin DA , SabatiniDM. Defining the role of mTOR in cancer.Cancer Cell12, 9–22 (2007).
- Guertin DA , SabatiniDM. An expanding role for mTOR in cancer.Trends Mol. Med.11, 353–361 (2005).
- Martin DE , HallMN. The expanding TOR signaling network.Curr. Opin. Cell Biol.17, 158–166 (2005).
- Harrington LS , FindlayGM, LambRF. Restraining PI3K: mTOR signalling goes back to the membrane.Trends Biochem. Sci.30, 35–42 (2005).
- Dos Santos S , DelattreAI, De Longueville F et al. Gene expression profiling of LPS-stimulated murine macrophages and role of the NF-kB and PI3K/mTOR signaling pathways. Ann. N.Y. Acad. Sci.1096, 70–77 (2007).
- Weinstein SL , FinnAJ, DaveSHet al. Phosphatidylinositol 3-kinase and mTOR mediate lipopolysaccharide-stimulated nitric oxide production in macrophages via interferon-β. J. Leukoc. Biol. 67, 405–414 (2000).
- Kristof AS , Marks-KonczalikJ, BillingsEet al. Stimulation of signal transducer and activator of transcription-1 (STAT1)-dependent gene transcription by lipopolysaccharide and interferon-γ is regulated by mammalian target of rapamycin. J. Biol. Chem. 278, 33637–33644 (2003).
- Farkas S , HornungM, SattlerCet al. Rapamycin decreases leukocyte migration in vivo and effectively reduces experimentally induced chronic colitis. Int. J. Colorectal Dis. 21, 747–753 (2006).
- Matsuda C , ItoT, SongJet al. Therapeutic effect of a new immunosuppressive agent, everolimus, on interleukin-10 gene-deficient mice with colitis. Clin. Exp. Immunol. 148, 348–359 (2007).
- Deore V , YewalkarN, BhatiaDet al. Synthesis and therapeutic evaluation of pyridyl based novel mTOR inhibitors. Bioorg. Med. Chem. Lett. 19, 2949–2952 (2009).
- Cota D , ProulxK, SmithKAet al. Hypothalamic mTOR signaling regulates food intake. Science 312, 927–930 (2006).
- Harrison DE , StrongR, SharpZDet al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 460, 392–395 (2009).
- Engelman JA . Targeting PI3K signalling in cancer: opportunities, challenges and limitations.Nat. Rev. Cancer9, 550–562 (2009).
- Liu P , ChengH, RobertsTMet al. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov. 8, 627–644 (2009).
- Brachmann S , FritschC, MairaSMet al. PI3K and mTOR inhibitors: a new generation of targeted anticancer agents. Curr. Opin. Cell Biol. 21, 194–198 (2009).
- Guertin DA , Sabatini,DM. The pharmacology of mTOR inhibition: the quest for effective cancer therapies reveals insight into the regulation and function of the mammalian target of rapamycin.Science Signaling2(67), 24 (2009).
- Laplante M , SabatiniDM. mTOR signaling at a glance.J. Cell Sci.122, 3589–3594 (2009).
- Liu Q , ThoreenC, WangJet al. mTOR mediated anticancer drug discovery. Drug Discov. Today Therapeutic Strat. 6(2), 47–55 (2010).
- Huang J , WuS, WuCLet al. Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors. Cancer Res. 69, 6107–6114 (2009).
- Raje N , KumarS, HideshimaTet al. Anderson Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood 104, 4188–4193 (2004).
- Vignot S , FaivreS, AguirreDet al. mTOR-targeted therapy of cancer with rapamycin derivatives. Annal. Oncology 16, 525–537 (2005).
- Hartford CM , RatainMJ. Rapamycin: something old, something new, sometimes borrowed and now renewed.Clin. Pharmacol. Ther.82, 381–388 (2007).
- Sarbassov DD , AliSMet al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 22, 159–168 (2006).
- Choi J , ChenJ, SchreiberSLet al. Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science 273, 239–342 (1996).
- Wullschleger S , LoewithR, HallMN. TOR signaling in growth and metabolism.Cell124, 471–484 (2006).
- Kurmasheva RT , HuangS, HoughtonPJ. Predicted mechanisms of resistance to mTOR inhibitors.Br. J. Cancer95, 955–960 (2006).
- Huang S , BjornstiMA, HoughtonPJ. Rapamycins: mechanism of action and cellular resistance.Cancer Biol. Ther.2, 222–232 (2003).
- Chen Y , ZhengYet al. Phospholipase D confers rapamycin resistance in human breast cancer cells. Oncogene 22, 3937–3942 (2003).
- Neuhaus P , KluppJ, LangrehrJM. mTOR inhibitors: an overview.Liv. Transplantation7, 473–484 (2001).
- Sehgal SN , BakerH, VezinaC. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization.J. Antibiot. (Tokyo)28, 727–732 (1975).
- Martel RR , KliciusJ, GaletS. Inhibition of the immune response by rapamycin, a new antifungal antibiotic.Can. J. Physiol. Pharmacol.55, 48–51 (1977).
- Cardenas ME , CruzMC, Del Poeta M et al. Antifungal activities of antineoplastic agents: Saccharomyces cerevisiae as a model system to study drug action. Clin. Microbiol. Rev.12, 583–611 (1999).
- Singh N , HeitmanJ. Antifungal attributes of immunosuppressive agents: new paradigms in management and elucidating the pathophysiologic basis of opportunistic mycoses in organ transplant recipients.Transplantation77, 795–800 (2004).
- Dumont FJ , SuQ. Mechanism of action of the immunosuppressant rapamycin.Life Sci.58, 373–395 (1996).
- Tamburini J , ChapuisN, BardetVet al. Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. Blood 111, 379–382 (2008).
- Tamburini J , GreenAS, BardetVet al. Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. Blood 114, 1618–1627 (2009).
- Menear KA , GomezS, MalaguKet al. Identification and optimisation of novel and selective small molecular weight kinase inhibitors of mTOR. Bioorg. Med. Chem. Lett. 19, 5898–5901 (2009).
- Richard DJ , VerheijenJC, YuKet al. Triazines incorporating (R)-3-methylmorpholine are potent inhibitors of the mammalian target of rapamycin (mTOR) with selectivity over PI3Kα. Bioorg. Med. Chem. Lett. 2010, 20, 2654–2657 (2010).
- Malagu K , DugganH, MenearKet al. The discovery and optimization of pyrido[2,3-d] pyrimidine-2,4-diamines as potent and selective inhibitors of mTOR kinase. Bioorg. Med. Chem. Lett. 19, 5950–5953 (2009).
- Garcia-Martinez JM , MoranJ, ClarkeRGet al. Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem. J. 421, 29–42 (2009).
- Zask A , VerheijenJC, CurranKet al. ATP-competitive inhibitors of the mammalian target of rapamycin: design and synthesis of highly potent and selective pyrazolopyrimidines. J. Med. Chem. 52, 5013–5016 (2009).
- Zask A , KaplanJ, VerheijenJCet al. Morpholine derivatives greatly enhance the selectivity of mammalian target of rapamycin (mTOR) inhibitors. J. Med. Chem. 52, 7942–7945 (2009).
- Richard DJ , VerheijenJC, CurranKet al. Incorporation of water-solubilizing groups in pyrazolopyrimidine mTOR inhibitors: discovery of highly potent and selective analogs with improved human microsomal stability. Bioorg. Med. Chem. Lett. 19, 6830–6835 (2009).
- Curran KJ , VerheijenJC, KaplanJet al. Pyrazolopyrimidines as highly potent and selective, ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 1-substituent. Bioorg. Med. Chem. Lett. 20, 1440–1444 (2010).
- Verheijen JC , RichardDJ, CurranKet al. 2-arylureidophenyl-4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)triazines as highly potent and selective ATP competitive mTOR inhibitors: optimization of human microsomal stability. Bioorg. Med. Chem. Lett. 20, 2648–2653 (2010).
- Zask A , VerheijenJC, RichardDJet al. Discovery of 2-ureidophenyltriazines bearing bridged morpholines as potent and selective ATP-competitive mTOR inhibitors. Bioorg. Med. Chem. Lett. 20, 2644–2647 (2010).
- Verheijen JC , YuK, Toral-BarzaLet al. Discovery of 2-arylthieno[3,2-d]pyrimidines containing 8-oxa-3-azabi-cyclo[3.2.1]octane in the 4-position as potent inhibitors of mTOR with selectivity over PI3K. Bioorg. Med. Chem. Lett. 20, 375–379 (2010).
- Dehnhardt CM , VenkatesanAM, SantosEDet al. Lead optimization of N-3-substituted 7-morpholinotriazolopyrimidines as dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors: discovery of PKI-402. J. Med. Chem. 53(2), 798–810 (2010).
- Venkatesan AM , DehnhardtCM, ChenZet al. Novel imidazolopyrimidines as dual PI3-kinase/mTOR inhibitors. Bioorg. Med. Chem. Lett. 20, 653–656 (2010).
- Tsou HR , MacEwanG, BirnbergGet al. Discovery and optimization of 2-(4-substituted-pyrrolo[2,3-b]pyridin-3-yl)methylene-4-hydroxybenzofuran- 3(2H)-ones as potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR). Bioorg. Med. Chem. Lett. 20, 2321–2325 (2010).
- Kaplan J , VerheijenJC, BrooijmansNet al. Discovery of 3,6-dihydro-2H-pyran as a morpholine replacement in 6-aryl-1H-pyrazolo[3,4-d]pyrimidines and 2-arylthieno[3,2-d]pyrimidines: ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR). Bioorg. Med. Chem. Lett. 20, 640–643 (2010).
- Knight SD , AdamsND, BurgessJLet al. Discovery of GSK2126458, a highly potent inhibitor of PI3K and the mammalian target of rapapmycin. ACS Med. Chem. Lett. 1(1), 39–43 (2010).
- Raynaud FI , EcclesSA, PatelSet al. Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941. Mol. Cancer Ther. 8(7), 1725–1738 (2009).
- Ihle NT , PowisG. Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy.Mol. Cancer Ther.8(1), 1–9 (2009).
- Marone R , CmiljanovicV, GieseBet al. Targeting phosphoinositide 3-kinase-moving towards therapy. Biochim. Biophys. Acta. 1784, 159–185 (2008).
- Maira SM , StaufferF, SchnellCet al. PI3K inhibitors for cancer treatment: where do we stand? Biochem Soc. Trans. 37, 265–272 (2009).
- Maira SM , FuretP, StaufferF. Discovery of novel anticancer therapeutics targeting the PI3K/AKt/mTOR pathway.Future Med. Chem.1(1), 137–155 (2009).
Patents
- Ariad Gene Therapeutics, Inc.: WO2007143212A1 (2006).
- Novartis Pharma Gmbh.: WO2007131689A2 (2007).
- Novartis Pharma Gmbh.: WO2007124252A2 (2007).
- Novartis Pharma Gmbh.: WO2007080124A1 (2007).
- Novartis Pharma Gmbh.: WO2007010012A2 (2007).
- Kudos Pharmaceuticals Ltd: WO2006090167A2 (2006).
- Synta Pharmaceuticals.: WO2005000404A2 (2005).
- Kudos Pharmaceuticals Ltd: US2008194546A1 (2008).
- Kudos Pharmaceuticals Ltd: WO2006090169A1 (2006).
- Kudos Pharmaceuticals Ltd: WO2007060404A1 (2007).
- Kudos Pharmaceuticals Ltd: US20080081809 (2008).
- Wyeth, John, And Brother Ltd: WO2008115974A2 (2008).
- Wyeth, John, And Brother Ltd: US2009098086A1 (2009).
- Wyeth, John, And Brother Ltd: WO2009070524A1 (2009).
- Wyeth, John, And Brother Ltd: WO2008116129A2 (2008).
- Astrazeneca Ltd: US20090018134A1 (2009)
- Astrazeneca Ltd: WO2008023159A1 (2009).
- Astrazeneca Ltd: WO2009007749A2 (2009).
- Astrazeneca Ltd: WO2008023180A1 (2008).
- Astrazeneca Ltd: WO2009007750A1 (2009).
- Astrazeneca Ltd: WO2009007751A2 (2009).
- Astrazeneca Ltd: WO2007080382A1 (2007).
- Astrazeneca Ltd: WO2007135398A1 (2007).
- Astrazeneca Ltd: WO2007129052A1 (2007).
- Astrazeneca Ltd: WO2006051270A1 (2006).